Latest / Bloomberg Intelligence / Rx Savings' Rea on Mylan Under Scrutiny for EpiPen Price(Audio)

Transcript

Rx Savings' Rea on Mylan Under Scrutiny for EpiPen Price(Audio) · Bloomberg Intelligence

• 0:01
  Speaker 1: The Global business News twenty four hours a day at
• 0:08
  Speaker 1: Bloomberg dot com, the radio plus Globo lact and on
• 0:11
  Speaker 1: your radio. This is a Bloomberg Business flag from Bloomberg
• 0:15
  Speaker 1: World Handquarters. I'm Charlie Pellett. The DAL, the SMP, NEZTAC
• 0:18
  Speaker 1: Hall declining. This update is brought to you by Sector
• 0:22
  Speaker 1: Spider E t F S. Why buy a single stock
• 0:25
  Speaker 1: when you can invest in the entire sector of visits
• 0:27
  Speaker 1: Sector s P d r S dot com or call
• 0:31
  Speaker 1: sector E t F stocks are lower right now, the
• 0:36
  Speaker 1: SMP five hundred index slumping three tenths of one percent
• 0:39
  Speaker 1: to twenty one eighty stocks declining as investors away Friday
• 0:43
  Speaker 1: speech from FED chair Janet Yellen, They'll be listening for
• 0:46
  Speaker 1: clues on when to expect higher borrowing costs. The DAL
• 0:50
  Speaker 1: is down thirty eight points to drop there of two
• 0:52
  Speaker 1: tenths of one percent, and as a STACK is down
• 0:54
  Speaker 1: twenty three a drop of five tenths of one percent.
• 0:57
  Speaker 1: The tenure down one thirty second, that yield one point
• 1:00
  Speaker 1: five Gold down one point three percent, dropping seventeen fifty
• 1:05
  Speaker 1: ounce crude oil West Texas Intermediate down two point nine percent.
• 1:11
  Speaker 1: I'm Charlie Palleton. That's a Bloomberg business flash. You're listening
• 1:18
  Speaker 1: to Taking Style with pin Box and Gablee. Hayes on
• 1:22
  Speaker 1: Bloomberg Radio. My Land and epi pens. Well, epi pens
• 1:27
  Speaker 1: are in the news because since two thousand and seven,
• 1:30
  Speaker 1: the price of fipens has increased by four hundred percent.
• 1:35
  Speaker 1: During that same time, the now chief executive of my Land,
• 1:40
  Speaker 1: her salary has increased more than six hundred and seventy
• 1:44
  Speaker 1: Here to tell us more is Michael Ray. He is
• 1:47
  Speaker 1: the chief executive of our ex Savings Solutions and he
• 1:51
  Speaker 1: is based in Overland Park, Kansas. Michael, thanks for being
• 1:55
  Speaker 1: with us. Tell us about EpiPens and why has the
• 1:59
  Speaker 1: price increased so much? Yeah, well, Pim, it's always a
• 2:03
  Speaker 1: pleasure to be with you. Um. You know, with the
• 2:06
  Speaker 1: Eppen situation, UM, you've got a couple of things, market
• 2:11
  Speaker 1: factors combined, and you've got the mergers of a couple
• 2:14
  Speaker 1: of companies. You've got a really big marketing campaign that's
• 2:17
  Speaker 1: driven um a bit of fear um in the market
• 2:21
  Speaker 1: and essentially, at the end of the day, UM that
• 2:24
  Speaker 1: that's increased the price. There's obviously been some price spikes,
• 2:28
  Speaker 1: but what EpiPen does is it. It's epineffern is the
• 2:31
  Speaker 1: active ingredient. It actually helps relax the smooth muscle in
• 2:35
  Speaker 1: the throat. And so what happens sometimes with kids with
• 2:38
  Speaker 1: a beasting or a peanut allergy, um, they may have
• 2:41
  Speaker 1: a reaction where their throat swallows up. The epanef worn
• 2:43
  Speaker 1: will actually um stop that from happening and could be
• 2:46
  Speaker 1: life saving, which is which is why it's such a
• 2:49
  Speaker 1: dilemma for a lot of parents on whether or not
• 2:51
  Speaker 1: they spend the six hundred bucks on it. And Michael,
• 2:54
  Speaker 1: you know, we have talked today about the CEO of
• 2:58
  Speaker 1: Milan how to brush her Her father is Democratic Senator
• 3:01
  Speaker 1: Joe Mansion. We've seen, um, some of these executives from
• 3:06
  Speaker 1: other pharmaceutical companies get called into Congress um to actually
• 3:12
  Speaker 1: talk about these price hikes, whether it's UH fame Martin
• 3:15
  Speaker 1: Shakreli at the former leader of Touring Pharmaceuticals, or executives
• 3:19
  Speaker 1: from Valiant. But when I think about this, uh, this
• 3:22
  Speaker 1: group of companies, this seems to be the one that
• 3:24
  Speaker 1: has the most general consumer recognition. This is the EpiPen.
• 3:28
  Speaker 1: You know, this is to your point, the one that
• 3:30
  Speaker 1: you grab if your kid does have a beasting. Does
• 3:33
  Speaker 1: this change the game at all for how a Congress
• 3:38
  Speaker 1: is looking at these companies and whether we see some
• 3:41
  Speaker 1: kind of congressional order and be for violin itself. Yeah,
• 3:45
  Speaker 1: that's a great question. I mean, I think when you
• 3:47
  Speaker 1: look at touring and you compare it to mylin UM,
• 3:50
  Speaker 1: with touring, you know, you've got a life or that
• 3:52
  Speaker 1: situation with their drug as well, UM usually usually in
• 3:56
  Speaker 1: some very sick HIV patients. In this case, now you're
• 3:58
  Speaker 1: dealing with children. UM, so you've got maybe even an
• 4:01
  Speaker 1: even more emotional component UM for some folks M on
• 4:05
  Speaker 1: that and so you know they really as a parent,
• 4:07
  Speaker 1: you know, speaking as as a parent, UM, it's pretty
• 4:10
  Speaker 1: difficult to say no, no matter what the cost is.
• 4:12
  Speaker 1: But that said, there's economics involved in their supply and demand,
• 4:15
  Speaker 1: and there's a breaking point. And I think that we've seen, um,
• 4:18
  Speaker 1: you know, seen a breaking point being reached, not just
• 4:21
  Speaker 1: in um, the case of touring with the very big
• 4:24
  Speaker 1: increase at one time, but also with that depen and
• 4:27
  Speaker 1: the smaller percentage increases. But overall UM really really inflating
• 4:33
  Speaker 1: you know, both their sales and net profits. You know,
• 4:38
  Speaker 1: you you you speak about supply and demand. Teva comes
• 4:41
  Speaker 1: to mind because they have an up and difference shot UM,
• 4:44
  Speaker 1: that is, you know, potentially being reviewed by the fd
• 4:47
  Speaker 1: as a competitor. Does this push that process to you know,
• 4:53
  Speaker 1: come through faster. Do we see some kind of speedy
• 4:56
  Speaker 1: review from the f d A as mylens going through
• 4:59
  Speaker 1: this kind of public right now? Yeah, I think you know,
• 5:02
  Speaker 1: there's I'm look, I'm all for competition, and I think
• 5:04
  Speaker 1: this really ties into your question about UM about bringing
• 5:08
  Speaker 1: executives to Washington. UM. I'm all for competition in the
• 5:11
  Speaker 1: free market, but I'm not sure why Teva necessarily gets
• 5:15
  Speaker 1: to jump the line UM in this case. Knowing that
• 5:19
  Speaker 1: you know, there is an epineffron auto injector that is
• 5:22
  Speaker 1: readily available. Most people don't know that. And so I
• 5:25
  Speaker 1: think this is a case where you know, information is power.
• 5:28
  Speaker 1: It's something that we UM really you know, push hard
• 5:31
  Speaker 1: on for our our health plan and sell funded clients. UM.
• 5:34
  Speaker 1: And it's really about information in the hands of the
• 5:37
  Speaker 1: of the person making the decision at the right time.
• 5:39
  Speaker 1: In the case of bringing UM, you know, more of
• 5:41
  Speaker 1: these executives to Washington, if there's going if there's actually
• 5:45
  Speaker 1: a goal, I'm all for it if there's actually something
• 5:47
  Speaker 1: that's going to result, um. But if it's if it's
• 5:49
  Speaker 1: just a parade um to kind of publicly parade them,
• 5:53
  Speaker 1: I don't think it's gonna it's gonna solve the problem
• 5:55
  Speaker 1: that we're all looking for at the end of the day.
• 5:57
  Speaker 1: And I think that really it should be people with
• 5:59
  Speaker 1: solutions be brought to Washington, because there are often times
• 6:02
  Speaker 1: things that can be done and something that we're definitely
• 6:05
  Speaker 1: advocating for the market. Well, just to give the context here, Michael,
• 6:10
  Speaker 1: EpiPens make up of my lands operating profits and the
• 6:18
  Speaker 1: same device cells in France for eighty five dollars. Is
• 6:23
  Speaker 1: there any real reason why something that's sold for well,
• 6:29
  Speaker 1: I don't know, fifty dollars, sixty dollars several years ago.
• 6:33
  Speaker 1: Is there anything in the EpiPen itself that has increased
• 6:37
  Speaker 1: so dramatically to make it now cost more than five Yeah,
• 6:42
  Speaker 1: to my knowledge. Now, I mean, I think it's effective marketing,
• 6:45
  Speaker 1: it's effective branding, um. And they've they've increased the demand
• 6:48
  Speaker 1: for for the product. But from a you know, cost
• 6:51
  Speaker 1: of components that go into the product, I'm not aware
• 6:54
  Speaker 1: of any any shortage, any price bike or anything like that,
• 6:58
  Speaker 1: all right, thanks very much, Michael Ray. He is the
• 7:01
  Speaker 1: founder and the chief executive of our X Savings Solutions.
• 7:05
  Speaker 1: They are based in Overland Park, Kansas. The shares of
• 7:08
  Speaker 1: my Land are down about four percent today at forty
• 7:12
  Speaker 1: dollars sixty four cents. And as you mentioned at the
• 7:16
  Speaker 1: very beginning, Alex the chief executive of my Land of Pharmaceuticals.
• 7:22
  Speaker 1: UH the daughter of Democratic Senator Joe Mansion of West
• 7:27
  Speaker 1: of Virginia, Heather Breash. She was president of my Land
• 7:31
  Speaker 1: in two thousand seven she earned two point four million
• 7:34
  Speaker 1: dollars and UH last year she made eighteen point nine
• 7:38
  Speaker 1: million dollars. This is Bloomberg coming up on taking stock,
• 7:47
  Speaker 1: will take stock of global foreign exchange markets. We'll find
• 7:51
  Speaker 1: out is the dollar over valued? And what will Janet Yellen,
• 7:55
  Speaker 1: Chair of the Federal Reserve, what will her speech mean
• 7:59
  Speaker 1: for dollars